Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab

ABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. ABP 980 is approved in the U...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Target Oncol
Autores principales: Kolberg, Hans-Christian, Colleoni, Marco, Santi, Patricia, Demetriou, Georgia Savva, Segui-Palmer, Miguel Angel, Fujiwara, Yasuhiro, Hurvitz, Sara A., Hanes, Vladimir
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6875516/
https://ncbi.nlm.nih.gov/pubmed/31620980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-019-00675-z
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares